ReviewFrontiers in immunology2021
LncRNAs and Rheumatoid Arthritis: From Identifying Mechanisms to Clinical Investigation.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Regulation of SNHG1, SNHG3, SNHG4 and SNHG5 in peripheral blood mononuclear cells in rheumatoid arthritis.Scientific reports · 2026Article
- Platelet-derived non-coding RNAs as emerging contributors to autoimmune inflammation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- A Potential Central Hub of Histamine in the Microbiota-Gut-Joint Axis in Rheumatoid Arthritis: Mechanisms and Translational Implications.International journal of molecular sciences · 2026Review
- Smart Polymer Nanoparticles: Targeting Macrophages/Fibroblasts and Modulating the Microenvironment for Rheumatoid Arthritis Therapy.International journal of nanomedicine · 2026Review
- Frontier research on mechanisms of bone destruction in rheumatoid arthritis.Frontiers in cell and developmental biology · 2026Review
- Blood-based epigenetic biomarkers in rheumatoid arthritis: current knowledge and future perspectives.Frontiers in immunology · 2026Review
- HAPLN1 Exhibits Dual Effects: Facilitating Extracellular Matrix Restoration while Enhancing Inflammatory Mediator Production in Arthritic Chondrocytes.Inflammation · 2025Article
- Noncoding RNAs in periodontitis: Progress and perspectives (Review).International journal of molecular medicine · 2025Review
- The potential role of long non-coding RNAs (HOTAIR and NEAT1) in patients with rheumatoid arthritis.Molecular biology reports · 2025Article
- Regulation of lncRNA NUTM2A-AS1 and CCR3 in the Clinical Response to a Plant-Based Diet in Rheumatoid Arthritis: A Pilot Study.Nutrients · 2025Article
- The double-edged sword of lncRNAs in rheumatoid arthritis: from controlling the disease to its progress.Clinical and experimental medicine · 2025Review
- The double-edged sword of lncRNAs in rheumatoid arthritis: from controlling the disease to its progress.Clinical and experimental medicine · 2025Review
- The Role and Mechanism of Protein Post‑Translational Modification in Rheumatoid Arthritis.Journal of inflammation research · 2025Review
- Extracellular derivatives for bone metabolism.Journal of advanced research · 2024Review
- Serum lncRNA ITGB2-AS1 and ICAM-1 as novel biomarkers for rheumatoid arthritis and osteoarthritis diagnosis.BMC medical genomics · 2024Article
- LncRNA MIAT suppresses inflammation in LPS-induced J774A.1 macrophages by promoting autophagy through miR-30a-5p/SOCS1 axi.Scientific reports · 2024Article
- Article
- miR-6089 may prevent the inflammatory events leading to cardiovascular disorders in RA patients.Heliyon · 2024Article
- Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review.ACS pharmacology & translational science · 2024Review
- Cartilage-Related Collagens in Osteoarthritis and Rheumatoid Arthritis: From Pathogenesis to Therapeutics.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a systemic chronic autoinflammatory disease, and the synovial hyperplasia, pannus formation, articular cartilage damage and bone matrix destruction caused by immune system abnormalities are the main features of RA. The use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) has achieved great advances in the therapy of RA. Yet there are still patients facing the problem of poor response to drug therapy or drug intolerance. Current therapy methods can only moderate RA progress, but cannot stop or reverse the damage it has caused. Recent studies have reported that there are a variety of long non-coding RNAs (LncRNAs) that have been implicated in mediating many aspects of RA. Understanding the mechanism of LncRNAs in RA is therefore critical for the development of new therapy strategies and prevention strategies. In this review, we systematically elucidate the biological roles and mechanisms of action of LncRNAs and their mechanisms of action in RA. Additionally, we also highlight the potential value of LncRNAs in the clinical diagnosis and therapy of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.